Skip directly to content

homepage-inflamation

APPLICATION DEADLINE EXTENSION: MAY 29th 2017

MISSION

Pfizer is committed to research in the Inflammation area and supports medical innovation through this Competitive Investigator Research Awards Program.
The mission of the Inflammation ASPIRE 2017 Research Awards is to support clinical research in Rheumatoid Arthritis (RA) and basic and translational research in Inflammatory Bowel Diseases (IBD) through a competitive grants program that advances medical knowledge in understanding the role of the Janus Kinase (JAK)–Signal Transducer and Activator of Transcription (STAT) pathways in Immune Mediated Inflammatory Diseases (IMID). Of particular interest is the effect of targeted inhibition of the JAK–STAT pathways as related to specific clinical effects examining either efficacy and/or safety outcomes and the role of the JAK–STAT pathways in IBD.

An independent committee of European medical experts in the field of Inflammation will review the research proposals and select the grant recipients.

This program provides research grants for studies designed and conducted by non-Pfizer physicians and scientists.

BACKGROUND

Intracellular signaling pathways play a critical role in the pathogenesis of IMIDs, such as RA or IBD. One of these pathways is the JAK–STAT pathway. Basic and clinical research has demonstrated that inhibition of the JAK–STAT pathway results in the reduction of inflammation and may therefore be a potential strategy to reduce the signs and symptoms of several IMID. However, many questions remain with respect to the role that JAK–STAT pathways play in inflammation. Furthermore, increased understanding of exactly how (specific) inhibition of JAK-STAT pathways may cause a certain clinical effect with respect to efficacy and safety outcomes in IMID is needed.

REQUEST FOR PROPOSALS

Pfizer invites investigators to apply for the Inflammation ASPIRE 2017 Research Awards through submission of research proposals with the primary objective to increase understanding of the role of the JAK–STAT pathways in RA or IBD and the effect of specific inhibition of the JAK–STAT pathways by targeting JAK on specific clinical effects looking at either efficacy and/or safety outcomes.

UPDATED AREAS OF FOCUS FOR THE 2017 ASPIRE AWARDS

The program focuses on clinical research in RA, and basic and translational research in IBD and may include, but will not be limited to, the following topics:

    Treatment optimization in RA

  • Predictors of response to JAK inhibitors
  • Treatment strategies of RA patients on JAK inhibitor treatment in sustained remission
  • Optimization of medical management of concomitant therapies with JAK inhibitors
  • Optimization of RA treatment management to avoid infections, i.e. herpes zoster (HZ)
  • Role of JAK pathway in IBD

  • Studies elucidating the mechanism of action of JAK inhibitors in the treatment of IBD at a molecular, tissue and organ level. Of particular interest, would be studies that identify specific biomarkers or pathways impacted by JAK inhibitors
  • Please note that animal models are considered of little value in this area and therefore animal studies will not be supported
  • RESEARCH EXPECTATION

    Within the proposed topics, investigators are expected to generate clinical data on treatment optimization with JAK inhibitors in RA and in-vitro data with the primary objective of further understanding the role of the JAK–STAT pathways in IBD. Project duration should not exceed two years.

    CRITERIA FOR SELECTION

    External Independent Review Committee

    The ASPIRE applications will be reviewed by an external independent review committee comprised of medical and scientific experts. Grants will be awarded based upon:

    • Scientific merit of the research proposal
    • Qualifications of the applicant
    • Relevance of proposed research to the program's mission
    • Evidence of the applicant's commitment to an academic research career
    • Evidence of a suitable research environment

    AVAILABLE AWARDS

    Pfizer is funding awards of 60,000 to a maximum of 80,000 Euros for each research project in IBD and 80,000 to a maximum of 120,000 Euros for each clinical project in RA. It is expected that the results will be presented at scientific meetings and published in peer-reviewed journals.

    DEADLINE FOR APPLICATION AND KEY DATES

    • Application submission start: 03 April 2017
    • APPLICATION DEADLINE EXTENSION: May 29th 2017
    • Award announcement: July 2017

    Date of preparation: May 2017
    PP-XEL-EUR- 0520